GSK/Valeant's epilepsy candidate retigabine shows potential in Phase III
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline/Valeant's first-in-class potassium channel opener, retigabine, has demonstrated a significant reduction in seizure frequency in adults with inadequately controlled partial-onset epilepsy in a Phase III study, RESTORE II, presented at the American Epilepsy Society meeting in Seattle, US.
You may also be interested in...
P&G to co-promote Somaxon's Silenor in the US
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GSK's shingles vaccine begins Phase III studies
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
Optimer's fidaxomicin filing accepted in EU
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.